We chat with Mike “Zappy” Zapolin to discuss his work with the Mind Army and Reborn, his latest directorial film.
Similar Posts
Sena Maria On The Benefits of Microdosing
In this episode, Sena Maria gives us an overview of her Microdosing Activation program and explains some of the benefits of microdosing.
NEW MindMed teaming up With Pfizer, J&J and Johns Hopkins on Digital Medicines? (MNMD, PFE, JNJ)
As technological change revolutionizes medicine and healthcare, how do we ensure that no-one, particularly members of vulnerable groups, get left behind?
This is the question that companies like MindMed (MNMD, MMED) , Johnson and Johnson (JNJ), and Pfizer(PFE) , as well as government organizations like the FDA, and universities like Johns Hopkins are trying to answer through collaborating with each other in a forum called The Digital Health Measurement Collaborative Community, or DATAcc.
Useful links:
https://datacc.dimesociety.org/
https://thecannabisstock.com/2021/08/03/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technology/
https://www.prnewswire.com/news-releases/healthcare-leaders-collaborate-on-digital-inclusion-initiatives-301341678.html
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #JNJ #Pfizer
Senator Scott Wiener Discusses Senate Bill 519
In this Psychedelic Spotlight exclusive, we speak with California Senator,…
Psilocybin Trial Treating Depression CRUSHES It [Are We At A Turning Point?]
Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment.
The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS!
The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world.
Though the study’s primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives.
And again, every secondary research objective heavily FAVORED psilocybin.
This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ)
Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
…
General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #psilocybin #shroomboom
Doug Drysdale On How CYB-003 Is Better Than Psilocybin
In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.
What to expect at a Co-Therapy Retreat Centre With Andrew Tansil
In this episode, we get into what to expect at a Psychedelic Retreat that offers Co-Therapy, and some serious transformational energy. Listen to Andrew from Sayulita Wellness Retreat speak about his life-changing revelation, and the reasons why folks come to Psychedelic Retreats.